Immunotherapy-Neurotoxicity Service

The Immunotherapy-Neurotoxicity National Advisory Panel is a national multidisciplinary advisory and management service for immune checkpoint inhibitor-related neurotoxicity. The service was established collaboratively between the National Hospital for Neurology and Neurosurgery (NHNN), University College London Hospitals (UCLH) and a nationwide oncology clinical team.

The advisory panel meet on alternative fridays at 4pm and accepts referrals from across the UK.

The advisory panel will accept referrals on the following conditions:

Triple M syndrome (myasthenia, myositis and myocarditis)
Immune-checkpoint inhibitor-related neuritis (ICI-neuritis)
ICI-myositis
ICI-myasthenia
ICI-encephalitis
ICI-aseptic meningitis
ICI-vestibulitis
ICI-ADEM
Or any other immune-related neurological manifestation of immunotherapy

Find further information, useful resources and how to refer patients on the UCLH website here.